The CD59 Knockout HeLa Polyclonal Cells are a human polyclonal knockout cell population derived from the HeLa cervical adenocarcinoma cell line, engineered via CRISPR/Cas9-mediated gene disruption to ablate expression of the CD59 gene. This product provides a heterogeneous pool of edited cells with loss-of-function mutations in CD59, enabling investigation of complement regulation and immune evasion mechanisms in a well-characterized cancer model. The polyclonal format retains genetic diversity, offering robustness for population-level functional studies without selecting a single clonal isolate.
HeLa cells are an immortalized epithelial cell line originating from a human cervical adenocarcinoma, widely employed as a foundational model in cancer biology, virology, and cell signaling research. These cells are HPV18-positive, with viral oncoproteins E6 and E7 functionally inactivating the tumor suppressors p53 and Rb, thereby driving uncontrolled proliferation. The adherent growth and robust manipulability of HeLa cells make them suitable for genetic perturbation, high-content imaging, and therapeutic screening. Their complement-competent nature, when cultured in appropriate serum conditions, allows direct assessment of complement-mediated cytotoxicity following CD59 disruption.
CD59 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that functions as a critical inhibitor of the terminal complement pathway. Mechanistically, CD59 binds to complement components C8 and C9, preventing the assembly and pore formation of the membrane attack complex (MAC, C5b-9), thus shielding host cells from complement-dependent lysis. Beyond its well-established role in innate immunity, CD59 also modulates adaptive immune responses by interacting with the T cell surface protein CD2 and influencing Lck/Fyn kinase activation downstream of T cell receptor signaling. Expression of CD59 can be upregulated by inflammatory cytokines such as TNF-alpha and IL-6, and its transcription is driven by the Sp1 transcription factor. Within the complement and coagulation network, CD59 operates alongside other regulators including CD55 (DAF), CD46 (MCP), and soluble Factor H, all cooperating to fine-tune complement activation on host cell surfaces. Disruption of CD59 consequently sensitizes cells to MAC deposition and alters T cell costimulatory dynamics.
In the HeLa cell context, knockout of CD59 yields a powerful model to dissect the interplay between complement resistance and tumor immune evasion. The loss of CD59-mediated protection renders these cells acutely susceptible to complement-dependent cytotoxicity, a phenotype that can be exploited to evaluate the efficacy of complement-inhibiting therapeutics or to study pathological conditions like paroxysmal nocturnal hemoglobinuria (PNH) where GPI anchor deficiency leads to CD59 absence on hematopoietic cells. Furthermore, since HeLa cells express HPV oncoproteins and exhibit deregulated proliferation, the CD59-knockout model allows researchers to examine how complement sensitivity influences tumor cell survival in an oncogenic background, potentially informing strategies to enhance antibody-based cancer therapies that rely on complement-dependent cytotoxicity.
This polyclonal knockout product is ideally suited for a breadth of investigative applications. Researchers can employ complement-mediated cytotoxicity assays to quantify susceptibility to serum lysis, or use C5b-9 deposition assays and immunofluorescence to visualize MAC formation on knockout cells. Western blotting and flow cytometry provide reliable tools to confirm CD59 protein loss and assess population-level editing efficiency. RT-qPCR allows transcriptional profiling of compensatory complement regulators. The model supports compound screening for inhibitors of complement activation, mechanistic studies of GPI anchor biosynthesis, and functional interrogation of T cell costimulation in the context of CD2-CD59 interactions. It also serves as a platform for PNH disease modeling and for exploring resistance mechanisms in antibody-dependent cell-mediated cytotoxicity. For further details, please contact Ascent Research.
